Prognostic role of neutrophil-to-lymphocyte ratio in advanced pancreatic ductal adenocarcinoma: Impact of baseline fluctuation and changes during chemotherapy

Tumori

Volumn 99, Issue 4, 2013, Pages 516-522

  Teo, MinYuen ^a   Sharial, Mohd Syahizul Nuhairy Mohd ^a   McDonnell, Felicity ^a   Conlon, Kevin C ^a   Ridgway, Paul F ^a   McDermott, Ray S ^a  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

Author keywords

Chemotherapy; Neutrophil to lymphocyte ratio; Pancreatic cancer; Prognostic marker

Indexed keywords

CAPECITABINE; CISPLATIN; ERLOTINIB; FLUOROURACIL; GEMCITABINE; LAPATINIB; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER PROGNOSIS; CANCER STAGING; CARCINOGENESIS; CELLULAR PARAMETERS; COHORT ANALYSIS; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUTROPHIL; NEUTROPHIL TO LYMPHOCYTE RATIO; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; TREATMENT DURATION; VERY ELDERLY;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, PANCREATIC DUCTAL; COHORT STUDIES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOCYTES; MALE; MIDDLE AGED; NEUTROPHILS; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 84890885973     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1177/030089161309900413     Document Type: Article

References (26)

1. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M: Pancreatic cancer. Lancet, 378: 607-620, 2011.
2. Sultana A, Smith CT, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P: Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol, 25: 2607-2615, 2007.
3. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W; National Cancer Institute of Canada Clinical Trials Group: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol, 25: 1960-1966, 2007.
4. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell, 144: 646-674, 2011.
5. Malka D, Hammel P, Maire F, Rufat P, Madeira I, Pessione F, Lévy P, Ruszniewski P: Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut, 51: 849-852, 2002.
6. Chu GC, Kimmelman AC, Hezel AF, DePinho RA: Stromal biology of pancreatic cancer. J Cell Biochem, 101: 887-907, 2007.
7. Tjomsland V, Niklasson L, Sandström P, Borch K, Druid H, brathäll C, Messmer D, Larsson D, Spanåques A: The desmoplastic stroma plays an essential role in the accumulation and modulation of infiltrated immune cells in pancreatic adenocarcinoma. Clin Dev Immunol, 2011: 212810, 2011.
8. Moore MM, Chua W, Charles KA, Clarke SJ: Inflammation and cancer: causes and consequences. Clini Pharmacol Ther, 87: 504-508, 2010.
9. Ruka W, Rutkowski P, Kaminska J, Rysinska A, Steffen J: Alterations of routine blood tests in adult patients with soft tissue sarcomas: relationships to cytokine serum levels and prognostic significance. Ann Oncol, 12: 1423-1432, 2001.
10. Ray-Coquard I, Cropet C, Van Glabbeke M: Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res, 69: 5383-5391, 2009.
11. Stathopoulos GP, Armakolas A, Tranga T, Marinou H, Stathopoulos J, Chandrinou H: Granulocyte colony-stimulating factor expression as a prognostic biomarker in non-small cell lung cancer. Oncol Rep, 25: 1541-1544, 2011.
12. Kasuga I, Makino S, Kiyokawa H, Katoh H, Ebihara Y, Ohyashiki K: Tumor-related leukocytosis is linked with poor prognosis in patients with lung carcinoma. Cancer, 92: 2399-2405, 2001.
13. Kuang DM, Zhao Q, Wu Y, Peng C, Wang J, Xu Z, Yin XY, Zheng L: Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J Hepatol, 54: 948-955, 2011.
14. Spicer JD, McDonald B, Cools-Lartigue JJ, Chow SC, Giannias B, Kubes P, Ferri LE: Neutrophils promote liver metastasis via Mac-1 mediated interactions with circulating tumor cells. Cancer Res, 72: 3919-3927 2012.
15. Manuel M, Tredan O, Bachelot T, Clapisson G, Courtier A, Parmentier G, Rabeony T, Grives A, Perez S, Mouret JF, Perol D, Chabaud S, Ray-Coquard I, Labidi-Galy I, Heudel P, Pierga JY, Caux C, Blay JY, Pasqual N, Ménétrier-Caux C: Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients. Oncoimmunology, 1: 432-440, 2012.
16. Borg C, Ray-Coquard I, Philip I, Gilles Clapisson, Bendriss-Vermare N, Menetrier-Caux C, Sebban C, Biron P, Blay JY: CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer. Cancer, 101: 2675-2680, 2004.
17. Lee Y, Kim SH, Han JY, Kim HT, Yun T, Lee JS: Early neutrophil-to- lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy. J Cancer Res Clin Oncol, 138: 2009-2016, 2012.
18. Chua W, Charles KA, Baracos VE, Clarke SJ: Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer, 104: 1288-1295, 2011.
19. Bambury RM, Teo MY, Power DG, Yusuf A, Murray S., Battley JE, Drake C, O'Dea P, Bermingham N, Keohane C, Grossman SA, Moylan EJ, O'Reilly S: The association of pretreatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme. J Neurooncol, Epub - update 2013.
20. An X, Ding P-R, Li Y-H, Wang FH, Shi YX, Wang ZQ, He YJ, Xu RH, Jiang WQ: Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer. Biomarkers, 15: 516-522, 2010.
21. Bhatti I, Peacock O, Lloyd G, Larvin M, Hall RI: Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. Am J Surg, 200: 197-203, 2010.
22. Garcea G, Ladwa N, Neal CP, Metcalfe MS, Dennison AR, Berry DP: Preoperative neutrophil-to-lymphocyte ratio (NLR) is associated with reduced disease-free survival following curative resection of pancreatic adenocarcinoma. World J Surg, 35: 868-872, 2011.
23. Wang DS, Luo HY, Qiu MZ, Wang ZQ, Zhang DS, Wang FH, Li YH, Xu RH: Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer. Med Oncol, Epub - update 2012.
24. Ong SL, Garcea G, Thomasset SC, Mann CD, Neal CP, Abu Amara M, Dennison AR, Berry DP: Surrogate markers of resectability in patients undergoing exploration of potentially resectable pancreatic adenocarcinoma. J Gastroint Surg, 12: 1068-1073, 2008
25. Bauer TM, El-Rayes BF, Li X, Hammad N, Philip PA, Shields AF, Zalupski MM, Bekaii-Saab T: Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials. Cancer, 119: 285-292, 2013.
26. Hess V, Glimelius B, Grawe P, Dietrich D, Bodoky G, Ruhstaller T, Bajetta E, Saletti P, Figer A, Scheithauer W, Herrmann R: CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol, 9: 132-138, 2008.